Intravitreal ranibizumab injection in the treatment of cystoid diabetic macular edema
DOI:
https://doi.org/10.31288/oftalmolzh201325660Keywords:
diabetic macular edema, ranibizumab, intravitreal injectionAbstract
The aim of the study was to investigate the efficacy of intravitreal injection of 0,5 mg ranibizumab in the treatment of cystoid diabetic macular edema as a monotherapy. In the study was included 41 eyes (type I of diabetes mellitus — 31 patient, type II of diabetes mellitus — 19 patients, blood glucose less than 13,0pMol/l) non-proliferative diabetic retinopathy (DR) — 78,0 %, preproliferative DR — 14,6 %, proliferative DR — 7,4 %. Macular thickness (MT) and foveal avascular zone (FAZ) in fluorescent angiography images and best corrected visual acuity (BCVA) were measured. During the year 1 bevacizumab injection to 7,3 %, 2 injections to 24,4 % and 3 injections to 68,3 % of patients were done. After the one year of the start of treatment MT significantly reduced from 506±20 pm to 376±21,9 pm, FAZ reduced from 1,1±0,24 mm2 do 0,9±0,24 mm2 and BCVA increased or stabilized in 63,4 % patients.
References
1.Махер Альзин. Прогноз положительного результата панмакулярной коагуляции «решетка» у больных с кистозным диабетическим макулярным отеком [Текст] / Махер Альзин, Н. Н. Уманец, 3. А. Розанова // Таврический медико-биологический вестник. - 2012. - том 15. - № 3. - С. 96- 99.
2.Науменко В. А. Эффективность нового метода диа-гностики и лазерного лечения отечных форм диабе-тической макулопатии // автореферат дисс канд мед наук. - Одесса, 2004 г.
3.Antcliff R. J. The pathogenesis of edema in diabetic maculopathy [Текст] / R. J. Antcliff, J. Marshall // Semin. Ophthalmol. - 1999. - № 14. - Р. 223- 232. https://doi.org/10.3109/08820539909069541
4.Arevalo J. F. Primary intravitreal bevacizumab for diffuse diabetic macular edema [Текст] / J. F. Arevalo, J. G. Sanchez, L. Wu [et al.] // Ophthalmology. - 2009.- № 116.- P. 1488- 1497.https://doi.org/10.1016/j.ophtha.2009.03.016
5.Erol N. Vision, retinal thickness, and avascular zone size after intravitreal bevacizumab for diabetic macular edema [Текст] / N. Erol, H. Gursoy, S. Kimion [et al.] // Adv Ther. - 2012. - № 4. - P. 359- 369.https://doi.org/10.1007/s12325-012-0009-9
6.Ferrara N. Vascular endothelial growth factor: basic science and clinical progress [Текст] / N. Ferrara // Endocr. Rev. - 2004. - № 25. - Р. 581-611.https://doi.org/10.1210/er.2003-0027
7.Gaudreault J. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administra¬tion [Текст] / J. Gaudreault, D. Fei, J. Rusit [et.al.] // I. O. V. S. - 2005.- Vol.6.- № 2.- P.726- 733.https://doi.org/10.1167/iovs.04-0601
8.Jonas J. B. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study [Текст] / J. B. Jonas, B. A. Kamppeter, B. Harder, [et al.] //J. Ocul.
Pharmacol. Ther. - 2006. - № 22. - Р. 200-207.
9.Klein R. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema [Текст] / R. Klein, B. E. Klein, S. E. Moss [et al.] // Ophthalmol¬ogy. - 1984. - № 91. - Р.1464- 1474.https://doi.org/10.1016/S0161-6420(84)34102-1
10.Lee C. M. Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results [Текст] / C. M. Lee, R. J. Olk // Ophthalmology.- 1991. - № 98. - Р.1594- 1602.https://doi.org/10.1016/S0161-6420(91)32082-7
11.Mitchell P. The RESTORE Study Ranibizumab Mono¬therapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema [Текст] / P. Mitchell, F Bandello, U. Schmidt-Erfurth [et al.] // Ophthalmol¬ogy. - 2011. - № 118. - Р.615- 625.
12.Murakami T. Foveal cystoids spaces are associated with enlarged foveal avascular zone and microaneuysms in diabetic macular edema [Текст]/ T. Murakami, K. Nishi-jima, A. Sakamoto [et al.] // Ophthalmology.- 2011.- № 118.- P.359- 367.https://doi.org/10.1016/j.ophtha.2010.03.035
13.Nguyen Q. D. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema [Текст] / Q. D. Nguyen, S. Tatlipinar, S. M. Shah, [et al.] // Am. J.Ophthalmol. - 2006. - № 142. - Р.961-969.https://doi.org/10.1001/archderm.142.8.969
14.Nguyen Q. D. Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study [Текст] / Q. D. Nguyen, S. M. Shah, A. A. Khwaja, [et al.] // Ophthalmology. - 2010. - № 117. - Р.2146 -2151.https://doi.org/10.1016/j.ophtha.2010.08.016
15.Pendergast S. D. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid [Текст] / S. D. Pendergast, T. S. Hassan, G. A. Williams [et al] // Am. J. Ophthalmol. - 2000. - № 130. - Р.178- 186.https://doi.org/10.1016/S0002-9394(00)00472-4
16.Tolentino M. J. Pathologic features of vascular endothe-lial growth factor-induced retinopathy in the nonhuman primate [Текст] / M. J. Tolentino, D. S. McLeod, M. Tao-moto, [et al.] // Am. J. Ophthalmol.- 2002.- № 133. - Р.373-85.https://doi.org/10.1016/S0002-9394(01)01381-2
17.Zimmet P. Global and societal implications of the diabetes epidemic [Текст] / P. Zimmet, K. G. Alberti, J. Shaw // Nature. - 2001. - № 414. - Р. 782- 787.https://doi.org/10.1038/414782a
Downloads
Published
Issue
Section
License
Copyright (c) 2013 Н. Н. Уманец, 3. А. Розанова, Махер Альзин
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
